Immune–epidermal dual targeting in psoriasis: emerging technologies and translational therapeutic strategies
British Journal of Dermatology · 08.09.2026
DOI: 10.1093/bjd/ljag390 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 08.09.2026. Verfasst von Meijun Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular…. Die Arbeit nennt 88 Literaturangaben. Gefördert von: Guizhou Science and Technology Partnership Initiative, Science and Technology Project of Guizhou, Graduate Education Teaching Reform Project of Zunyi Medical University.
Abstract (Originalsprache)
Although immune-targeted therapies, particularly agents targeting the interleukin (IL)-23/IL-17 axis, have markedly improved short-term disease control in psoriasis, inadequate responses in a subset of patients and relapse after treatment discontinuation remain unresolved challenges. One possible reason is that immune-centred therapies may not fully address the active contribution of epidermal keratinocytes to inflammatory amplification and disease persistence. In this review, we integrate immune-driven inflammation and epidermal amplification mechanisms from a loop- and network-based perspective, and propose an immune–epidermal dual-targeting framework centred on proinflammatory feedback between immune cells and keratinocytes. We systematically summarize three potential implementation routes: combination therapy, single-agent dual targeting and blockade of bridging nodes within immune–epidermal feedback circuits. We further discuss the potential roles and realistic boundaries of artificial intelligence and multi-omics analysis, organoids and engineered skin models, and precision local delivery technologies in target discovery, mechanistic validation and therapeutic translation. Importantly, this framework is not intended to replace existing therapeutic paradigms, but rather to refine their mechanistic interpretation and extend future therapeutic strategies. It may provide additional translational opportunities for stratified, stage-specific and precision management of psoriasis, although several components remain at the stage of mechanistic research and clinical validation.
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Educati…
- Biology and Medicine Program, School of Bioengineering, Zhuhai Campus, Zunyi Medical University, Zhuhai, Guangdong, China.
- Department of Emergency Medicine, The First Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
- Department of Epidemiology and Health Statistics, Zunyi Medical University, Zunyi, Guizhou, China.
- Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China.
ORCID-Profile: Meijun Liu, Cong Yang
Förderung
- Guizhou Science and Technology Partnership Initiative
- Science and Technology Project of Guizhou
- Graduate Education Teaching Reform Project of Zunyi Medical University
Zitieren
APA
Liu, M., Dong, P., Yang, C., Xu, X., Wu, Y., Chen, J., Tian, W., Wang, H., Luo, J., & Qin, M. (2026). Immune–epidermal dual targeting in psoriasis: emerging technologies and translational therapeutic strategies. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag390
Vancouver
Liu M, Dong P, Yang C, Xu X, Wu Y, Chen J, et al. Immune–epidermal dual targeting in psoriasis: emerging technologies and translational therapeutic strategies. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag390
BibTeX
@article{Liu2026,
author = {Liu, Meijun and Dong, Pinzhi and Yang, Cong and Xu, Xiaorong and Wu, Yingnong and Chen, Jin and Tian, Wenjie and Wang, Haiyan and Luo, Junmin and Qin, Ming},
title = {Immune–epidermal dual targeting in psoriasis: emerging technologies and translational therapeutic strategies},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljag390}
}
EUVIMED